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ABSTRACT
Objective. To review the available research to describe the clinical characteristics and neoplastic associations of patients with 
gamma-aminobutyric acid receptor type B (GABAB-R) autoantibodies. 
Methods. Literature was reviewed on PubMed, Mendeley literature search, and the American Academy of Neurology database for 
articles published from June 2008 to October of 2018 using a variety of key words. These key words include: „gamma-aminobutyric 
acid seizures,” „gamma-aminobutyric acid limbic encephalitis”, „GABA(B) receptor antibodies,” „autoimmune encephalitis,” „autoimmu-
ne epilepsy,” „GABA(B) encephalitis, „ and “GABA paraneoplastic.” With the results, the papers were reviewed in a systematic manner. 
Results. A total of 10 studies were reviewed. A summary of the demographic, clinical, and serological findings of the cases 
detailed in the literature are provided. An additional illustrative case is described. In total, 94 patients were reviewed. 
Conclusions. GABAB-R autoimmune disease is characterized by refractory seizures or status epilepticus and frequent associa-
tion with small cell lung cancer. Additionally, a substantial minority of patients have non-inflammatory CSF.
Key words: Gamma-aminobutyric acid seizures, gamma-aminobutyric acid receptor type B, GABA(B) receptor antibodies,  
autoimmune encephalitis, autoimmune epilepsy, GABA-B encephalitis, GABA limbic encephalitis, GABA paraneoplastic  
(Neurol Neurochir Pol 2019; 53 (1): 1–7)
Introduction
The field of autoimmune neurology has evolved rapidly 
in the years following the discovery of N-methyl-D-aspartate 
receptor (NMDA-R) encephalitis in 2007 [1]. As more neural 
autoantibodies have been discovered, cases of encephalitis 
previously presumed to be viral or idiopathic have been 
determined to be autoimmune in aetiology [2]. Gamma-
-aminobutyric acid receptor type B (GABAB-R) antibody 
autoimmune encephalitis, first described in the literature 
in 2010 by Lancaster et al. [3], has been followed by several 
additional case series and retrospective studies [4, 5]. 
As more clinical cases have been reported, the profile of 
the clinical, radiological, and serological characteristics of 
GABAB-R autoimmunity has continued to expand. While 
symptoms of limbic encephalitis (seizures, confusion, and 
memory loss) and frequent association with small cell lung 
cancer (SCLC) were characteristics originally proposed 
[3, 5]memory loss, and confusion, compatible with limbic 
encephalitis (LE, additional associated features have become 
apparent, including: status epilepticus, ataxia, epileptiform 
electroencephalogram (EEG) findings, and sometimes benign 
cerebrospinal fluid (CSF) studies [5–7]. Given the neoplastic 
associations of GABAB-R antibody encephalitis, and its ten-
dency to respond to immunosuppressive treatment [5] prompt 
recognition of the disorder is crucial as this can improve 
oncologic and neurologic outcomes. 
GABAB-R is a G-protein coupled receptor known to play 
a role in the suppression of neural or seizure activity [8] 
and is widely distributed in the hippocampus, thalamus and 
cerebellum [9]. GABA receptor is composed of GABAB1 and 
GABAB2 subunits. Binding of GABA to the GABAB1 subunit 
results in conformational changes, causing inhibition of 
neuronal firing activity principally by inhibiting presynaptic 
calcium channels [8]. There is evidence that a lack of normal 
GABAB-R structure and function can lead to spontaneous se-
izures [10]. Autoantibodies in the CSF of anti-GABA receptor 
encephalitis patients prevent activation of GABA receptors in 
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vitro by blocking receptor function without altering receptor 
surface density [11]. 
In this study, we review the current literature relating 
to GABAB-R autoimmunity, describing the clinical features, 
laboratory evaluation, oncologic associations, and treatment 
response of the disorder in a comprehensive manner. We will 
also provide an illustrative new clinical case of GABAB-R anti-
body encephalitis on which the diagnosis was obtained post-
mortem, as testing was unavailable at the time of presentation. 
State of the art
We identified a total of 94 confirmed cases of GABAB-
-R encephalitis, including case series from Lancaster et al. 
[3], Boronat et al. [4], Höftberger et al. [5], Guan et al. [6], 
Onugoren et al. [7], Kim et al. [12], and Chen et al. [13]. 
Additionally, several case reports, including one of our own, 
were included in the analysis [14–16]. All studies were retro-
spective. The average patient age was 59.6 years, with a range 
of 16 to 84 years. We only included patients of 16 years or 
older, given the frequently distinct paraneoplastic associa-
tions in paediatric patients [17]. However, we do recognise 
that, in the paediatric literature, GABAB-R encephalitis has 
been rarely reported, including a patient as young as three 
years old [18]. The male to female ratio was 59:35, with ma-
les comprising 62.8% (59/94) of the total number of cases. 
While most studies focus on Caucasian patients, the studies 
by Guan, Kim, and Chen have described the disorder in an 
East Asian population (n = 34). 
Patients most commonly presented with seizures, 
which were diagnosed in 84.0% (79/94) of cases on initial 
evaluation, with status epilepticus in 9.6% (9/94). Limbic 
symptoms characterised by confusion, disorientation, or 
behavioural change were seen in 67.1% (51/76) of patients 
at the time of presentation, whereas gait ataxia and gait 
instability were seen in 11.7% (11/94). The presenting 
symptoms are summarised in Table 1. Of all patients, 14.9% 
(14/94) ultimately developed coma or required an Intensive 
Care Unit (ICU) level of care for airway support or ventila-
tor management. An atypical case with coexistent anti-Hu 
and anti-CV2 autoantibodies was described with vertigo, 
hiccups, and vomiting, and was ultimately found to have 
brainstem involvement [14]. A summary of the symptoms 
encountered throughout the course of illness is presented in 
Table 2. The mean follow-up for cases with clearly defined 
data was 10.4 months, with a range from hospital discharge 
to 90 months (n = 66).
CSF findings
Of the cases with available CSF data, 59.3% (51/86) had 
CSF pleocytosis, and 43.9% (29/66) had elevated protein in 
CSF. Testing for GABAB-R autoantibodies was more sensitive 
in CSF than serum, with autoantibodies for GABAB-R iden-
tified in 98.3% (71/72) of subject CSF and 88.1% (69/77) of 
serum samples. 
Imaging findings
Magnetic resonance imaging (MRI) brain findings appe-
ared to have a strong predilection for the temporal lobes, with 
54.8% (51/94) of cases having either unilateral or bilateral 
temporal lobe hyperintensity on MRI brain T2. Of patients 
with temporal lobe hyperintensity on brain MR T2 imaging, 
bilateral temporal lobe hyperintensity occurred in 59.5% 
(25/42) of cases with available data. 
Table 1. Summary of the most commonly encountered presenting symptoms
Study Subjects Seizures Status Epilepticus Ataxia Confusion/Behavioural Change
Lancaster [3] 15 13 3 0 2
Boronat [4] 11 9 1 1 9
Höftberger [5] 20 18 0 1 17
Guan [6] 18 16 0 2 ND
Onugoren [7] 10 8 2 3 8
Kim [12] 5 3 0 0 5
Chen [13] 11 11 3 1 9
Alexopoulos [14] 1 0 0 0 0
Jarius [15] 1 0 0 1 0
Mimbrera [16] 1 0 0 1 0
Illustrative case 1 1 0 1 1
Total: 94 79 9 11 51 (n = 76)
Percentage: 84.0% 9.6% 11.7% 67.1%
ND — no data
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Electrophysiologic studies
EEG was documented for 66 patients, and 57.6% (38/66) 
had either temporal lobe seizures, interictal epileptiform 
abnormalities, or focal temporal slowing. 
Oncologic association
Neoplasm was detected in 49.5% (46/93) of cases, 
with 91.3% (42/46) of the neoplastic cases being small 
cell lung cancer. There were three patients assumed to be 
SCLC based on a diagnosis of lung cancer and a clinical 
history that did not have a final pathologic confirmation 
[6]. Additional associated neoplasms reported include: 
one neuroendocrine tumour [3], one carcinoid of the 
thymus [4] one type B1 thymoma [14], and one melanoma 
[15]. The patient with type B1 thymoma had associated 
anti-Hu and anti-CV2 antibodies, and the patient with 
melanoma had associated Glutamic Acid Decarboxilase 
(GAD-65) antibodies, whereas the patients with associated 
neuroendocrine tumour and carcinoid of the thymus had 
no reported additional antibodies. The youngest patient 
with reported SCLC was a 42 year-old female [19]. The 
most commonly reported autoantibodies associated with 
GABAB-R autoimmune disease were anti-Hu (10.8%, 
9/83), anti-SOX1 (10.8%, 9/83), anti-GAD65 (8.5%, 8/94), 
and N-type voltage gated calcium antibodies (4.8%, 4/83). 
Isolated cases with associated voltage-gated potassium 
channel, BR serine/threonine-protein kinase 2, NMDA-R, 
and CV2 autoantibodies have also been described. 
Treatment outcome
Outcomes demonstrate a robust response to either immu-
notherapy or a combination of immunotherapy and cancer 
treatment when appropriate, with 86.3% (63/73) of patients 
treated either demonstrating partial or complete recovery. Of 
those treated with immunosuppressive agents, 34.2% (25/73) 
of patients demonstrated a complete response, as defined by 
a return to a prior baseline or modified Rankin scale of 0–1, 
depending on the metric used. 
The most common immunosuppressive agents utilised 
were corticosteroids, IVIg, plasmapheresis, and steroid spa-
ring agents. Tables 3A and 3B summarise treatment types and 
responses. Outcomes in patients without immunotherapy 
and/or cancer treatment were poor, with 6 out of 9 (66.7%) 
dying. Interestingly, the two reported by Guan to have sur-
vived without immunotherapy and/or cancer treatment were 
treated with AEDs [6]. However, exact time to follow-up for 
these patients was not available, beyond that it was at least 
one month. Of the four patients treated with only AEDs, one 
demonstrated complete recovery, one demonstrated partial 
improvement, one remained stable without improvement, and 
the remaining one died. Due to the high mortality of SCLC, 
control of the underlying neoplasm was often the long-term 
limiting factor in patients with SCLC. 
Illustrative case 
In 2003, we encountered an 84 year-old gentleman with 
a history of heavy cigarette smoking, alcohol abuse, and atrial 
Table 2. Summary of the symptoms encountered during illness
Study Subjects Seizure GTC  
Seizure
Status  
Epilepticus
Memory  
Impairment
Confusion Agitation/
Behavioural 
change
Coma/
ICU
Ataxia
Lancaster [3] 15 15 8 3 15 15 5 4 1
Boronat [4] 11 8 ND 1 6 4 4 ND 1
Höftberger [5] 20 20 ND 1 20 20 ND 1 2
Guan [6] 18 17 17 4 12 ND 11 4 3
Onugoren [7] 10 8 8 2 6 5 5 2 3
Kim [12] 5 3 3 0 2 5 5 0 0
Chen [13] 11 11 11 3 9 7 9 1 1
Alexopoulos 
[14]
1 0 0 0 0 0 0 0 0
Jarius [15] 1 0 0 0 0 0 1 0 1
Mimbrera [16] 1 0 0 0 1 1 1 1 1
Illustrative 
case
1 1 1 1 1 1 0 1 1
Total: 94 83 15 72 58 (n = 76) 41(n = 74) 14 14
Percentage: 88.30% 16.00% 76.80% 76.30% 55.40% 14.90% 14.90%
ND — no data
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fibrillation who presented due to an unwitnessed presumed 
first generalised seizure with associated cognitive decline and 
ataxia with subacute gait instability. His initial neurologic 
examination was notable for intact cognition, reduced left he-
mibody light touch, left greater than right heel to shin ataxia, 
left greater than right finger to nose dysmetria, and gait ataxia. 
On day 12, repeat brain MRI was performed with and 
without demonstrated right mesial temporal lobe hyperin-
tensity on T2 imaging with increased restricted diffusion 
of the right mesial temporal lobe, insula, and adjacent basal 
ganglia (Fig. 1). Lumbar puncture was performed, with CSF 
laboratory values of: < 1 WBC, 20 RBC, normal glucose, 
protein 70, NSE elevated 31.6, and two oligoclonal bands. 
CSF infectious studies were all negative, including: HSV PCR, 
fungal studies, AFB culture, viral culture, Cryptococcus Ag, 
EBV, and West Nile Ag. 
The patient experienced rapidly progressive cognitive 
decline with a parallel worsening seizure course, with obtun-
dation and non-convulsive status epilepticus NCSE within 
21 days (Fig. 2), followed by death. Seizures arose from the 
right hemisphere and were refractory to phenytoin with par-
tial EEG response to high dose fosphenytoin and valproate 
combination therapy. Fine needle aspirate of a pulmonary 
mass was positive for SCLC. 
This patient’s case was reviewed retrospectively in 2018, 
and it was proposed that GABAB-R autoimmune encephali-
tis was the most likely cause of death based on the patient’s 
clinical characteristics of ataxia with seizures progressing to 
status epilepticus [4] imaging profile consistent with limbic 
encephalitis, small-cell lung cancer association [5] and CSF 
without pleocytosis [4]. Laboratory testing of stored patient’s 
serum and CSF by cell based assays were both positive for 
GABAB-R antibodies, confirming the diagnosis 15 years later. 
Clinical implications
The number of identified cases of GABAB-R antibody au-
toimmunity available for review has expanded in the literature 
Table 3 A. Treatment responses in patients treated with immunosuppression, AED, or no treatment. One unidentified patient was treated with chemotherapy
Patients Treated Full Recovery Partial Recovery No Response 
Steroids 16 9 (56.2%) 7 (43.8%) 0
IvIg 15 6 (40%) 6 (40%) 3 (20%)
Steroids + IVIG1 13 5 (33.5%) 7 (53.8%) 1 (7.7%)
Steroids + PLEX 5 1 (20%) 2 (40%) 2 (40%)
Steroids+IVIG+PLEX 2 0 2 0
Steroid Sparing Agent + Corticoste-
roid
3 1 1 1
Steroid Sparing Agent + IVIG or PLEX 
± Steroids
5 0 4 (80%) 1 (20%)
AED Only 4 1 1 2
No Treatment 6 0 0 6
Total: 69 23 30 16
Percentage: 33.3% 43.5% 23.2%
Table 3 B. Treatment responses in patients treated with chemotherapy or combined chemotherapy and immunosuppression. All patients in this category 
had confirmed neoplasm. Some patients had additional radiotherapy
Patients Treated Full Recovery Partial Recovery No Response 
Chemo only 6 0 4 2
Chemo + corticosteroids 1 1 0 0
Chemo + IVIG 2 1 1 0
Chemo + Steroids + IVIG 9 1 6 2
Corticosteroids + IVIG±PLEX+Chemo 1 0 1 0
Chemo + Steroid Sparing Agent + Ste-
roids + Chemo
1 0 1 0
Total: 20 3 13 4 
Percentage: 15% 65% 20%
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since the original description in 2010. As a result, a distin-
ctive clinical syndrome has become increasingly solidified, 
characterised by the cardinal features of refractory seizures 
or status epilepticus and frequent SCLC association. This re-
view demonstrates that the disease is more common in males 
than in females, that bilateral temporal lobe hyperintensity 
is a very frequent radiographic finding, that a substantial 
minority have noninflammatory CSF, and that ataxia is more 
frequent in these patients than most physicians had previously 
appreciated. The included data from Asian countries reveals 
that GABAB-R autoimmunity is probably not bound by race 
or ethnicity and most likely has a similar clinical syndrome 
worldwide, as the frequency of SCLC is high. The study also 
highlights that other associated neoplasms besides SCLC 
may be present in a small group of patients, suggesting that 
a comprehensive oncologic evaluation is warranted. 
While features of GABAB-R Ab mediated autoimmune 
disease can overlap with other common autoimmune diseases 
of the central nervous system (CNS), GABAB-R autoim-
munity should be suspected over NMDA-R encephalitis in 
individuals with older average age of onset, with the average 
of onset being 59 years versus 21 respectively [20]. GABAB-R 
Figure 2. EEG demonstrating non-convulsive status epilepticus, with right hemisphere predominance
Figure 1. Brain MRI DWI sequence with restricted diffusion of the 
right mesial temporal lobe, insula, and basal ganglia (A,B) and 
corresponding brain MRI T2 hyperintensity (C,D)
A B
C D
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autoimmunity is also more common in males (2:1), whereas 
NMDA-R autoimmune encephalitis is female predominant 
(8:1). Additionally, GABAB-R autoimmunity is more likely 
to present with seizures or associated ataxia and has diffe-
rent oncologic associations (SCLC versus ovarian teratoma) 
compared to NMDA-R autoimmune encephalitis [21]. While 
anti-Hu autoantibodies are commonly seen in association 
with SCLC, with a similar average age of onset (63 years) as 
GABAB-R autoimmunity, it is much more likely to present 
with paraneoplastic peripheral neuropathy than seizure or 
limbic encephalitis [22]. In cases of isolated ataxia in asso-
ciation with SCLC, anti-Hu and anti-GABAB-R antibodies 
should be strongly considered in the differential. 
The recognition of GABAB-R autoimmunity has impor-
tant clinical implications for patient outcomes, as untreated 
patients are more likely to die or progress to coma. The recog-
nition that CSF can be non-inflammatory is important, as CSF 
pleocytosis is often used as a clinical justification for empiric 
treatment of suspected autoimmune neurological disorders 
while waiting for autoantibody testing results. Additionally, it 
has been recently reported that patients with antibodies targe-
ting cell surface proteins can often have a non-inflammatory 
CSF [23]. The retrospective diagnosis in our patient deceased 
15 years earlier was made possible by the subsequent discovery 
and characterisation of the clinical, imaging, and laboratory 
findings of GABAB-R autoimmune encephalitis. 
Aggressive treatment with immunosuppression is war-
ranted in the event of suspected GABAB-R autoimmune 
encephalitis, given the high potential for improvement, and 
the deleterious outcomes in patients who are not treated. 
None of the untreated patients in the literature have recovered 
spontaneously. The available data on treatment and response 
is likely influenced by the tendency to treat more responsive 
cases with corticosteroid agents alone, and then subsequently 
add further treatments to the regimen for refractory cases. Pa-
tients treated with corticosteroids alone versus IVIg alone did 
show a more robust treatment response on average (56.2% vs 
40% complete recovery). However, given the small number of 
patients, the lack of randomisation, and the retrospective data 
collection, no definitive conclusions as to the superiority of 
different immunosuppressive agents can be drawn. Treatment 
with a combination of chemotherapy and immunosuppres-
sion probably implied a poorer oncologic picture, so it is not 
surprising that response rates were not as favourable in this 
group. The five-year survival rate of SCLC is less than 10% 
[24] which ultimately will limit the life expectancy in patients 
found to have associated SCLC, but immunosuppressive 
therapies can still often lead to improvement in symptoms 
attributable to GABAB-R autoimmune encephalitis.
Clinicians should consider a diagnosis of GABAB-R au-
toimmune encephalitis in patients with new onset refractory 
seizures with associated SCLC with or without ataxia, even 
in the absence of CSF pleocytosis. It would be best to assess 
both serum and CSF samples, but CSF has the higher yield of 
detection based on available data. In adult patients with suspec-
ted or confirmed GABAB-R autoimmune encephalitis, an initial 
chest CT to screen for SCLC is appropriate [25]. However, if 
chest CT is negative with positive serum or CSF GABAB-R 
antibodies, whole body PET-scan is indicated, as this has been 
demonstrated to be superior to CT alone when screening for 
occult neoplasm in the setting of paraneoplastic antibodies [25, 
26]. While the youngest patient on record with associated SCLC 
was 42 years of age, it is reasonable to screen younger adults 
found to have GABAB-R antibodies, given the high oncologic 
association, close to 50%. If a neoplasm is discovered, oncology 
consultation should be sought so that appropriate oncological 
therapies can be administered [22, 27]. In the event that a neo-
plasm is not identified on initial screening, we recommend 
following the screening guidelines drawn up by the European 
Federation of Neurological Societies [25].
Future directions
An area for potential future study could be assessing the 
effectiveness of different types of AEDs in cases of GABAB-
-R associated epilepsy, particularly those cases with status 
epilepticus. Further long-term cognitive outcome follow-up 
data is also needed. Additionally, as more cases are reported, 
the understanding of the epidemiology and clinical characte-
ristics of GABAB-R autoimmunity will continue to increase.
Ethical approval was not necessary for preparation of 
this article.
This publication was prepared without any external so-
urces of funding.
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